ArticleAtherosclerosis2021
Lipid-lowering therapies: Better together.
Article in Atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Considerations on the sustainability of hypercholesterolemia treatment in the context of new drugs on the market: data from Campania, Italy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Evaluating the effects of bempedoic acid on lipid profiles and cardiovascular risk: An umbrella review of meta-analyses.Qatar medical journal · 2025Article
- Article
- Myeloid BAF60a deficiency alters metabolic homeostasis and exacerbates atherosclerosis.Cell reports · 2023Article
- Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.Journal of the American Heart Association · 2023Observational
- Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.Viruses · 2023Article
- Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).Journal of cachexia, sarcopenia and muscle · 2022Review
- Atherosclerosis: From Molecular Biology to Therapeutic Perspective.International journal of molecular sciences · 2022Article
- 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.Archives of medical science : AMS · 2022Article
- CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities.Metabolites · 2021Review
- Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel.Journal of clinical medicine · 2021Review
- Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.Metabolites · 2021Article
- Review
- Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey.Journal of clinical medicine · 2021Article
- Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies.Current atherosclerosis reports · 2021Review
- Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.International journal of molecular sciences · 2021Review
- PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.Archives of medical science : AMS · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33482997What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.